Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Novavax Inc (NVAX) Price & Performance

iShares MSCI United Kingdom (FTSE)Trade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI United Kingdom (FTSE) vs Novavax Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $48.34, while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

EWUNVAX
Sector
Broad Market / FactorHealth
52-Week High
$48.68$11.19
52-Week Low
$40.90$6.22
Market Cap
$1.31B
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI United Kingdom (FTSE)

EWU, the iShares MSCI United Kingdom ETF, trades at $48.38, down 0.23% on the day, with a bullish technical signal driven by moving averages. The ETF tracks UK large-cap equities, facing mixed sentiment from oil price volatility and geopolitical tensions in the Middle East. Recent institutional activity includes Balefire LLC acquiring shares and Bank of America reducing its stake, reflecting divergent views on UK market exposure.

The outlook for EWU hinges on UK economic resilience amid political transitions and energy market fluctuations. Opportunities include diversification into developed market leaders, but risks involve sustained oil price pressures and regional instability. Analyst consensus remains neutral, with the ETF serving as a tactical play on British equities rather than a growth-centric investment.

Novavax Inc

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.

Returns comparison

Trailing returns across standard periods

About iShares MSCI United Kingdom (FTSE)

EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.

Read more on EWU

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX